Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J. Frank, Sara Mainardi, Antonio Mulero‐Sánchez et al.|Cell Reports Medicine|2022Cited by 39
Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal AdenocarcinomaKatrin J. Ciecielski, Sara Mainardi, Astrid Bosma et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 2